2022-002441-18Ongoing
A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca ABEU Clinical Trials Register
VerifiedEU Clinical Trials Register
Study focus
- Disease/Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Sponsor & location
- Primary sponsor
- AstraZeneca AB
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
1. Confirmed primary diagnosis of moderate to severe COPD as per FEV1/FVC < 0.7, and post-BD FEV1 ≥ 25% predicted)
ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2022-002441-18
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2022-002441-18 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca AB and is currently Ongoing. The study focuses on Chronic Obstructive Pulmonary Disease (COPD).
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.